Barclays
NUTX

Barclays’s Nutex Health NUTX Stock Holding History

Barclays’s Portfolio NUTX Stock Details NUTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.84M Buy
22,485
+4,598
+26% +$583K ﹤0.01% 1982
2026
Q1 		$1.7M Buy
17,887
+9,824
+122% +$1.2M ﹤0.01% 2451
2025
Q4 		$1.33M Buy
8,063
+3,155
+64% +$418K ﹤0.01% 3239
2025
Q3 		$507K Sell
4,908
-1,770
-27% -$174K ﹤0.01% 3803
2025
Q2 		$831K Buy
+6,678
New +$863K ﹤0.01% 3460
2023
Q4 		– Sell
-444
Closed -$13.5K – 5314
2023
Q3 		$13.5K Buy
444
+14
+3% +$675 ﹤0.01% 4253
2023
Q2 		$27.2K Sell
430
-423
-50% -$36.3K ﹤0.01% 4070
2023
Q1 		$129K Buy
853
+404
+90% +$81.8K ﹤0.01% 4046
2022
Q4 		$128K Buy
449
+438
+3,982% +$84.1K ﹤0.01% 4092
2022
Q3 		$2K Sell
11
-2
-15% -$848 ﹤0.01% 4635
2022
Q2 		$6K Buy
+13
New +$15.3K ﹤0.01% 4751

Other funds holding NUTX

PP
Pertento Partners London, United Kingdom $1.86B AUM 53.86% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
WC
Winmill & Co Walpole, New Hampshire $452M AUM 56.84% 1-Year Est. Return
Focus Partners Wealth
Focus Partners Wealth Boston, Massachusetts $97.6B AUM 29.43% 1-Year Est. Return

Barclays's NUTX Position: Q2 2026 in Review

Barclays increased its Nutex Health (NUTX) stake by 26% in Q2 2026, buying an estimated $583K and bringing the position to 22,485 shares worth $3.84M. The position accounts for ﹤0.01% of the portfolio, ranked #1982.

Barclays first reported a position in NUTX in Q2 2022 and has held it in 11 quarters since. 154 funds tracked by Wall St. Rank hold NUTX as of Q2 2026.

  • Barclays held 22,485 shares of Nutex Health worth $3.84M as of Q2 2026.
  • Barclays bought 4,598 Nutex Health shares in Q2 2026, an estimated $583K.
  • Nutex Health made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #1982 holding.
  • Barclays first reported a position in Nutex Health in Q2 2022 and has held it in 11 quarters since.
  • 154 funds tracked by Wall St. Rank held Nutex Health as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.